Chimeric molecules providing targeted costimulation for adoptive cell therapy
AssigneeInstil Bio (UK) Limited
InventorsJohn Bridgeman, Robert Hawkins, Ruben Rodriguez, Sujita Sukumaran, Xingliang Zhou, Eric Gschweng
Life of this patent
Estimating the term…
Abstract
The present invention relates to a chimeric molecule useful in adoptive cell therapy (ACT), and cells comprising the same. The chimeric molecule can act as a modulator of cellular activity enhancing responses when an endogenous T-cell receptor (TCR) is engaged with its cognate antigen. The present invention also provides proteins, nucleic acids encoding the chimeric molecule and therapeutic uses thereof.
Claims25
A fusion protein comprising:
- (a) a binding domain, wherein the binding domain comprises:
- an L-CDR1 sequence comprising the amino acid sequence of SEQ ID NO:
- 168, an L-CDR2 sequence comprising the amino acid sequence of SEQ ID NO:
- 169, an L-CDR3 sequence comprising the amino acid sequence of SEQ ID NO:
- 170, an H-CDR1 sequence comprising the amino acid sequence of SEQ ID NO:
- 171, an H-CDR2 sequence comprising the amino acid sequence of SEQ ID NO:
- 172, and an H-CDR3 sequence comprising the amino acid sequence of SEQ ID NO:
- 173;
- (b) an amino acid sequence of SEQ ID NO:
- 162 linked to the binding domain;
- (c) an amino acid sequence of SEQ ID NO:
- 163 linked to (b);
- (d) an amino acid sequence of SEQ ID NO:
- 164 linked to (c);
- and
- (e) an amino acid sequence of SEQ ID NO:
- 165 linked to (d).
A fusion protein comprising the amino acid sequence of SEQ ID NO:
- 166 or 167.
A nucleic acid which encodes a protein comprising the amino acid sequence of SEQ ID NO:
- 166 or 167.
A cell which expresses a protein comprising the amino acid sequence of SEQ ID NO:
- 166.
Dependencies are inferred from the claim text.